anti-osteoporosis

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].

Compound 133, also known as Anti-osteoporosis agent-7, is a potential anti-osteoporosis agent that exhibits significant inhibition of osteoclast formation.

Anti-osteoporosis agent-4 (Compound 11h) suppresses the differentiation of primary osteoclasts and attenuates RANKL-induced osteoclastogenesis, effectively inhibiting osteoclast formation with an IC50 value of 358.29 nM, and impedes the activation of the PI3K AKT and IκBα NF-κB signaling pathways [1].

Anti-osteoporosis agent-2 (Compound 10) inhibits RANKL-induced osteoclast differentiation [1].

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

1. L-Arginine (L-Arg) exhibits anti-atherosclerotic effect. 2. L-Arginine and soy enriched diet are effective in prevention of osteoporosis associated with diabetes mellitus. 3. Exogenous L-Arginine could enhance neonate lymphocyte proliferation through an interleukin-2-independent pathway. 4. A combination of oral L-citrulline and L-Arginine effectively and rapidly augments NO-dependent responses at the acute stage.

Zoledronic acid monohydrate (CGP 42446) is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.

ONO-5334 is a selective, orally active and potent histone K inhibitor with anti-SAR-COV-2 and anti-bone resorption activity for the study of osteoporosis.

Syringin (eleutheroside-b) is a compound with antitumor, antiproliferative, immunomodulatory and platelet aggregation inhibiting effects.

Epimedin A has anti-osteoporosis activities in vivo.

KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt β-catenin pathway, thereby promoting osteoblast differentiation.

Saikosaponin A has a variety of pharmacological benefits, including antiepileptic, anti-osteoporosis, antioxidant, anti-in ammatory, immunomodulatory, and anti-bacterial activities. It can effectively attenuate neuropathic pain in CCI rats by inhibiting the activation of p38 MAPK and NF-κB signaling pathways in spinal cord. It can inhibit NMDA receptor current and persistent sodium current, and inhibit the TNF-α level, the IL-1β production, and cysteine-aspartic acid protease (caspase)-1 activity.

Toddaculine may be beneficial for the prevention and treatment of osteoporosis, it can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1 2, and p38 MAPK signaling pathways, but can induce differentiation and mineralization of osteoblasts by regulating differentiation factors. Toddaculine also may serve as a pharmacological prototype for the development of novel anti-leukemic agents, it displays a dual effect as a cell differentiating agent and apoptosis inducer in U-937 cells.

1. Geraniin has a protective effect against OVX-induced rat osteoporosis. 2. Geraniin has cytotoxic activity towards cancer cells in vitro and in vivo. 3. Geraniin exerts inhibitory effects on osteoclast differentiation in vitro and suppresses Ti particle

Blosozumab (LY2541546), an anti-sclerostin (SOST) antibody, promotes bone formation while decreasing bone resorption, with potential applications in osteoporosis research [1] [2].

1. Sweroside possesses strong hepatoprotective effect. 2. Sweroside is a promising osteoporosis therapeutic natural product, has anti-osteoporotic effect on the human MG-63 cells and rat osteoblasts.

Morusignin L, an active compound, exhibits anti-osteoporosis properties [1] [2].

BMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.BMP agonist 2 is an osteoinductive cytokine that promotes the production of bone tissue, and can be used in the study of senile osteoporosis (SOP).

Baohuoside I (Icariside-II) is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.

Baohuoside aglycone possesses cardioprotective effect in prevention of ischemia/ reperfusion injury and reduce the myocardial infraction, the mechnism is due to the reduction of the injury of free radicals. Baohuoside VII in vivo exhibits significant anti

ISX-3 is a potent pro-osteogenic and anti-adipogenic agent. ISX-3 can increase the expression of PPARγ. ISX-3 can be for the research of osteopenia and osteoporosis.

(S,S)-Secoisolariciresinol diglucoside ((S,S)-SDG) is a lignan present in flaxseed with anti-inflammatory, antioxidant, anti-microbial and neuroprotective properties and can be used in the study of obesity, arthritis and osteoporosis.

6,4'-Dihydroxy-7-methoxyflavanone is a biologically active compound isolated from the heartwood of Dalbergia odorifera T. Chen (Leguminosae) with antioxidant, anti-inflammatory and neuroprotective effects. 6,4'-Dihydroxy-7-methoxyflavanone can be used in studies about the treatment of osteoclastogenic bone diseases such osteoporosis, rheumatoid arthritis and periodontal diseases.